Schuster, Anne L. R.
Hampel, Heather
Paskett, Electra D.
Bridges, John F. P.
Funding for this research was provided by:
Ohio State University Comprehensive Cancer Center
National Cancer Institute (U24 CA252977-01)
Article History
Accepted: 20 September 2022
First Online: 27 October 2022
Declarations
:
: Anne L.R. Schuster and John F.P. Bridges declare they have no conflicts of interest. Electra Paskett has received grants, paid to the institution, from Merck Foundation, Pfizer, and Genentech for work outside this project. Heather Hampel is on the scientific advisory boards for Genome Medical, Invitae Genetics, and Promega; is a consultant for 23andMe, AIM Specialty Health, and GI OnDemand; and has stock/stock options in GI OnDemand and Genome Medical.
: All authors contributed to the conception of this commentary. Material preparation, literature review, and synthesis were performed by ALRS, who also wrote the first draft of the manuscript. All authors commented on previous versions of the manuscript, and read and approved the final version.
: This work was funded by the Ohio State University Comprehensive Cancer Center, and in part from a Grant from the National Cancer Institute (U24 CA252977-01).